Cite
mTOR Inhibition Impairs the Activation and Function of Belatacept-Resistant CD4 + CD57 + T Cells In Vivo and In Vitro.
MLA
Herr, Florence, et al. “MTOR Inhibition Impairs the Activation and Function of Belatacept-Resistant CD4 + CD57 + T Cells In Vivo and In Vitro.” Pharmaceutics, vol. 15, no. 4, Apr. 2023, p. 1299. EBSCOhost, https://doi.org/10.3390/pharmaceutics15041299.
APA
Herr, F., Dekeyser, M., Le Pavec, J., Desterke, C., Chiron, A.-S., Bargiel, K., Mercier, O., Vernochet, A., Fadel, E., & Durrbach, A. (2023). mTOR Inhibition Impairs the Activation and Function of Belatacept-Resistant CD4 + CD57 + T Cells In Vivo and In Vitro. Pharmaceutics, 15(4), 1299. https://doi.org/10.3390/pharmaceutics15041299
Chicago
Herr, Florence, Manon Dekeyser, Jerome Le Pavec, Christophe Desterke, Andrada-Silvana Chiron, Karen Bargiel, Olaf Mercier, Amelia Vernochet, Elie Fadel, and Antoine Durrbach. 2023. “MTOR Inhibition Impairs the Activation and Function of Belatacept-Resistant CD4 + CD57 + T Cells In Vivo and In Vitro.” Pharmaceutics 15 (4): 1299. doi:10.3390/pharmaceutics15041299.